{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:20:46Z","timestamp":1789161646551,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo Inc.","award":["2016\/0158"],"award-info":[{"award-number":["2016\/0158"]}]},{"name":"Daiichi Sankyo Inc.","award":["2019\/052-1"],"award-info":[{"award-number":["2019\/052-1"]}]},{"name":"Daiichi Sankyo Inc.","award":["PI18\/01340"],"award-info":[{"award-number":["PI18\/01340"]}]},{"name":"Daiichi Sankyo Inc.","award":["PI19\/00730"],"award-info":[{"award-number":["PI19\/00730"]}]},{"name":"Daiichi Sankyo Inc.","award":["FI19\/00059"],"award-info":[{"award-number":["FI19\/00059"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe","award":["2016\/0158"],"award-info":[{"award-number":["2016\/0158"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe","award":["2019\/052-1"],"award-info":[{"award-number":["2019\/052-1"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe","award":["PI18\/01340"],"award-info":[{"award-number":["PI18\/01340"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe","award":["PI19\/00730"],"award-info":[{"award-number":["PI19\/00730"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe","award":["FI19\/00059"],"award-info":[{"award-number":["FI19\/00059"]}]},{"name":"Instituto de Salud Carlos III","award":["2016\/0158"],"award-info":[{"award-number":["2016\/0158"]}]},{"name":"Instituto de Salud Carlos III","award":["2019\/052-1"],"award-info":[{"award-number":["2019\/052-1"]}]},{"name":"Instituto de Salud Carlos III","award":["PI18\/01340"],"award-info":[{"award-number":["PI18\/01340"]}]},{"name":"Instituto de Salud Carlos III","award":["PI19\/00730"],"award-info":[{"award-number":["PI19\/00730"]}]},{"name":"Instituto de Salud Carlos III","award":["FI19\/00059"],"award-info":[{"award-number":["FI19\/00059"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to identify risk factors for their occurrence. Among 571 newly diagnosed AML patients, 26 (4.6%) developed fatal cardiac events, and among 525 treated patients, 19 (3.6%) experienced fatal cardiac events (CI: 2% at 6 months; 6.7% at 9 years). Prior heart disease was associated with the development of fatal cardiac events (hazard ratio (HR) = 6.9). The CI of non-fatal cardiac events was 43.7% at 6 months and 56.9% at 9 years. Age \u2265 65 (HR = 2.2), relevant cardiac antecedents (HR = 1.4), and non-intensive chemotherapy (HR = 1.8) were associated with non-fatal cardiac events. The 9-year CI of grade 1\u20132 QTcF prolongation was 11.2%, grade 3 was 2.7%, and no patient had grade 4\u20135 events. The 9-year CI of grade 1\u20132 cardiac failure was 1.3%, grade 3\u20134 was 15%, and grade 5 was 2.1%; of grade 1\u20132, arrhythmia was 1.9%, grade 3\u20134 was 9.1%, and grade 5 was 1%. Among 285 intensive therapy patients, median overall survival decreased in those experiencing grade 3\u20134 cardiac events (p &lt; 0.001). We observed a high incidence of cardiac toxicity associated with significant mortality in AML.<\/jats:p>","DOI":"10.3390\/cancers15082267","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T01:35:00Z","timestamp":1681349700000},"page":"2267","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"15","author":[{"given":"Blanca","family":"Boluda","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8804-3878","authenticated-orcid":false,"given":"Antonio","family":"Solana-Altabella","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cano","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-4091","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-369X","authenticated-orcid":false,"given":"Evelyn","family":"Acu\u00f1a-Cruz","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Torres-Mi\u00f1ana","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Rodr\u00edguez-Veiga","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Navarro-Vicente","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8051-5933","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-Campuzano","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Garc\u00eda-Ruiz","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Lloret","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-3656","authenticated-orcid":false,"given":"Pedro","family":"Asensi","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Osa-S\u00e1ez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Aguero","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rodr\u00edguez-Serrano","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-2986","authenticated-orcid":false,"given":"Francisco","family":"Buend\u00eda-Fuentes","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5341","authenticated-orcid":false,"given":"Juan Eduardo","family":"Meg\u00edas-Vericat","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7286-9555","authenticated-orcid":false,"given":"Beatriz","family":"Mart\u00edn-Herreros","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Barrag\u00e1n","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8144-7995","authenticated-orcid":false,"given":"Claudia","family":"Sargas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-1558","authenticated-orcid":false,"given":"Maribel","family":"Salas","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA"},{"name":"Center for Real-World Effectiveness and Safety of Therapeutics (CREST), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Wooddell","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-9738","authenticated-orcid":false,"given":"Charles","family":"Dharmani","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-1177","authenticated-orcid":false,"given":"Miguel A.","family":"Sanz","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"De la Rubia","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia, 46001 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute Myeloid Leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage Regimens Using Conventional Chemotherapy Agents for Relapsed\/refractory Adult AML Patients: A Systematic Literature Review","volume":"97","author":"Sanz","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaccao.2019.10.008","article-title":"Symptomatic Heart Failure in Acute Leukemia Patients Treated With Anthracyclines","volume":"1","author":"Kang","year":"2019","journal-title":"JACC CardioOncology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline Chemotherapy and Cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive Heart Failure in Patients Treated with Doxorubicin: A Retrospective Analysis of Three Trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00277-003-0615-3","article-title":"Prolonged Monitoring of Troponin T for the Detection of Anthracycline Cardiotoxicity in Adults with Hematological Malignancies","volume":"82","author":"Auner","year":"2003","journal-title":"Ann. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.1995.13.11.2827","article-title":"Idarubicin Cardiotoxicity: A Retrospective Study in Acute Myeloid Leukemia and Myelodysplasia","volume":"13","author":"Anderlini","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status & Future Directions","volume":"16","author":"Baer","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ctrv.2017.11.009","article-title":"Management of QT Prolongation Induced by Anti-Cancer Drugs: Target Therapy and Old Agents. Different Algorithms for Different Drugs","volume":"63","author":"Coppola","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia (QuANTUM-R): A Multicentre, Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Giudice, V., Vecchione, C., and Selleri, C. (2020). Cardiotoxicity of Novel Targeted Hematological Therapies. Life, 10.","DOI":"10.3390\/life10120344"},{"key":"ref_14","first-page":"LB-339","article-title":"Cause of Death in Cancer Survivors","volume":"72","author":"Ning","year":"2012","journal-title":"Cancer Res. 103rd Annu. Meet. Am. Assoc. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_17","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer."},{"key":"ref_18","unstructured":"(2022, December 14). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations from an International Expert Panel, on Behalf of the European LeukemiaNet","volume":"115","author":"Estey","year":"2010","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/1078155219873014","article-title":"Evaluation of Cardiomyopathy in Acute Myeloid Leukemia Patients Treated with Anthracyclines","volume":"26","author":"Mort","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.18.00313","article-title":"Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes among Children Treated in the AAML0531 Clinical Trial: A Report from the Children\u2019s Oncology Group","volume":"37","author":"Getz","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","article-title":"Prevalence, Management, and Clinical Consequences of QT Interval Prolongation during Treatment with Arsenic Trioxide","volume":"32","author":"Roboz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_25","first-page":"1","article-title":"Quizartinib Prolonged Survival vs Placebo plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18\u201375 Years with Newly Diagnosed FLT3-ITD+ AML","volume":"6","author":"Erba","year":"2022","journal-title":"Present. EHA Congr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-017-3004-z","article-title":"Assessment of Late Cardiomyopathy by Magnetic Resonance Imaging in Patients with Acute Promyelocytic Leukaemia Treated with All-Trans Retinoic Acid and Idarubicin","volume":"96","author":"Igual","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hegazy, M., Ghaleb, S., and Das, B.B. (2023). Diagnosis and Management of Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Children. Children, 10.","DOI":"10.3390\/children10010149"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/hematology.2021000268","article-title":"Minimizing Car Diac Tox Ic Ity in Chil Dren with Acute Mye Loid Leu Ke Mia","volume":"2021","author":"Narayan","year":"2021","journal-title":"Hematology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-023-00159-0","article-title":"Efficacy and Safety of Cardioprotective Drugs in Chemotherapy-Induced Cardiotoxicity: An Updated Systematic Review & Network Meta-Analysis","volume":"9","author":"Mir","year":"2023","journal-title":"Cardio-Oncology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e27308","DOI":"10.1002\/pbc.27308","article-title":"Role of ACE Inhibitors in Anthracycline-Induced Cardiotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"65","author":"Gupta","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00280-019-03856-9","article-title":"A Phase 2 Study to Assess the Pharmacokinetics and Pharmacodynamics of CPX-351 and Its Effects on Cardiac Repolarization in Patients with Acute Leukemias","volume":"84","author":"Lin","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2021-149704","article-title":"Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents","volume":"138","author":"Johnson","year":"2021","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-022-00969-w","article-title":"Clonal Hematopoiesis and Cardiovascular Disease: Deciphering Interconnections","volume":"117","author":"Stein","year":"2022","journal-title":"Basic Res. Cardiol."},{"key":"ref_35","first-page":"55","article-title":"Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia","volume":"19","author":"Herrero","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/10428194.2020.1839650","article-title":"Impact of Combinations of Single-Nucleotide Polymorphisms of Anthracycline Transporter Genes upon the Efficacy and Toxicity of Induction Chemotherapy in Acute Myeloid Leukemia","volume":"62","author":"Herrero","year":"2021","journal-title":"Leuk. Lymphoma"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2267\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:15:04Z","timestamp":1760123704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15082267"],"URL":"https:\/\/doi.org\/10.3390\/cancers15082267","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}